Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 4,089,577	$ 6,763,848
General and administrative	3,985,298	3,425,833
Total operating expenses	8,074,875	10,189,681
Other income (expense):
Interest income (expense), net	1,971	(1,057)
Foreign currency gain	136,211	521,983
Total other income	138,182	520,926
Net loss	(7,936,693)	(9,668,755)
Other comprehensive loss:
Foreign currency translation	(65,505)	(402,850)
Total comprehensive loss	$ (8,002,198)	$ (10,071,605)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.36)	$ (0.46)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.36)	$ (0.46)
Weighted-average common shares outstanding, basic (in shares)	21,901,531	21,186,827
Weighted-average common shares outstanding, diluted (in shares)	21,901,531	21,186,827